CDK7 and esophageal squamous cell carcinoma: These findings highlight that the CDK7/9 inhibitor SNS-032 is a promising antitumor agent against ESCC cells and warrants a clinical trial to further assess its efficacy in patients with ESCC, especially with metastasis.